A phase 2, randomized study of nivolumab or nivolumab plus...

European Urology Supplements 2019 / 03 Vol. 18; Iss. 1

A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT

Witjes, J.A., Gschwend, J., Palou, J., Meng, M., Chang, S., Shore, N., Konety, B., Steinberg, G., Nishiyama, H., Taylor, J.A., Elegbe, A., Lambert, A., Zhu, L., Ishii, Y., Maeda, T., Raybold, B., Gros
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
18
Journal:
European Urology Supplements
DOI:
10.1016/S1569-9056(19)31328-4
Date:
March, 2019
File:
PDF, 111 KB
2019
Conversion to is in progress
Conversion to is failed